About this trial
The goal of this observational study is to identify biomarkers and host factors associated with dengue severity in patients from dengue-endemic regions. The main question it aims to answer is:
Can multi-omics approaches predict disease severity and identify key factors contributing to severe dengue infections?
Participants will include individuals with dengue infection, and the study will analyze their blood samples using multi-omics techniques to uncover host immune responses, disease pathogenesis, and cellular pathway interactions. The study will also assess the role of primary and secondary infections, virus serotypes, and immunological factors in disease progression. Findings aim to support disease management, improve severity prediction, and identify potential therapeutic targets to prevent severe outcomes.
Eligibility criteria
Qualifiers
Myalgia, arthralgia
Nausea and/or vomiting
Rashes
Leukopenia Group 2: DENV with warning signs This cohort will include patients with the above symptoms and any of the following clinical signs.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Infection and no infection
Treatment groups
Sponsors and collaborators
Karolinska Institutet
Lead sponsor
BIO BOX GUATEMALA ONG DE INVESTIGACIÓN, SERVICIOS Y DE MEDIO AMBIENTE
Collaborator
DEVKI DEVI FOUNDATION SOCIETY, India
Collaborator
MANIPAL ACADEMY OF HIGHER EDUCATION, India
Collaborator
Artemis Medicare Services Ltd., India
Collaborator